Humacyte, Inc.

Humacyte, Inc. (Nasdaq: HUMA) is a clinical-stage regenerative medicine company that became publicly traded in August 2021 through a merger with Alpha Healthcare Acquisition Corp., a blank-check vehicle sponsored by Alpha Healthcare Partners. The transaction marked one of the higher-profile biotech SPAC deals of that period, bringing Humacyte's pipeline of bioengineered human acellular vessels into the public markets under the HUMA ticker. The company, which targets vascular surgery and trauma applications, has remained listed on Nasdaq following the combination. Its June 2024 Form 8-K filing reflects ongoing public-company reporting obligations as the company advances its regenerative medicine programs. For full filing history, sponsor details, and deal metrics on HUMA and hundreds of other SPAC transactions, sign up for a SpacDesk account at spacdesk.com.